Key Highlights

  • Underlying NPAT rose 2.9% to A$636.8 million for the year to 30 June 2026.
  • Group operating profit rose 6.7% to A$813.5 million, and group Revenue rose 5.9% to A$9,115.2 million.
  • The full-year ordinary Dividend rose 6.7% to 19.2 cents per share, fully franked.
  • Management expects resident Health Insurance margins to be broadly consistent in FY27, while non-resident policies declined.

Why does a health insurer that grew policyholders and lifted its dividend still face questions about the year ahead? Medibank Private's (ASX:MPL) FY26 result, released on 20 August 2026, showed modest Underlying Profit growth and a higher dividend, but also rising costs, a decline in non-resident policies and management guidance that resident health insurance margins would be broadly consistent in FY27.

The central development

For the year to 30 June 2026, Medibank reported underlying net profit after tax of A$636.8 million, up 2.9%. The full-year ordinary dividend rose 6.7% to 19.2 cents per share, fully franked.

How Medibank makes money

Its core is resident health insurance: customers pay premiums, and Medibank pays claims to hospitals, doctors and other providers. Profit comes from the gap between premiums and claims and expenses, known as the gross margin, plus Investment income on the funds it holds.

Two other segments matter. Non-resident cover, mostly for international students and visitors, earns premiums from people temporarily in Australia. Medibank Health provides services such as virtual care, health management and related offerings, and reported segment profit up 31.3% to A$100.7 million in FY26.

Customers and claims

Medibank added 22,100 net resident policyholders during the year. Non-resident policy units fell 2.3%, mainly because of fewer students under tighter migration settings.

The policyholder growth shows the core Franchise is still expanding, which is useful because health insurers' profit depends on retaining and attracting a broad base of members whose average claims cost is manageable. The fall in non-resident units shows that Earnings are exposed to government policy settings outside the company's control.

Costs, Capital and regulation

Expenses growing faster than revenue growth of 5.9% is a trend worth monitoring, as it can compress margins if premium increases are limited.

The Health Insurance required capital ratio was 13.3%, above the company's target range, with Australian Prudential Regulation Authority supervisory adjustments partly responsible. Holding capital above target is a conservative position, but it can mean that cash is tied up rather than returned to shareholders or invested.

Premium increases in Australian private health insurance are approved by the federal government each year, so insurers cannot freely reprice. That constrains margins when claims Inflation runs ahead of approved increases.

FY27 outlook

Management expects FY27 resident health insurance gross margins to be broadly consistent with FY26, and continued encouraging growth in non-resident and Medibank Health. CEO David Koczkar said household budgets remain under pressure.

Those comments point to a likely trade-off. Pressure on household budgets can lead members to downgrade cover or drop it, while the insurer's own cost growth needs to be funded.

Sector and competitive position

private health insurance market is dominated by a few large groups, including Medibank, Bupa, HCF, nib holdings and Australian Unity, alongside a number of smaller funds. Competition is based on price, perceived value, Brand and digital experience. Medibank's scale and dual-brand approach give it reach across market segments, while its health services segment is an attempt to diversify beyond insurance margins.

In October 2022 it disclosed a major cyber attack, and the aftermath included regulatory and legal matters.

Material risks

Regulatory pricing. Annual premium increases require government approval, which can limit pass-through of cost inflation.

Household affordability. Pressure on budgets can lead to downgrades or lapses and weaker Volume growth.

Non-resident decline. Migration settings reduce student numbers, which pressures that segment.

Cost growth. Expenses rose 7.1% in FY26, faster than revenue.

Capital and acquisitions. A high required capital ratio and further acquisitions could affect capital returns, and acquisitions carry integration risk.

Cyber and operational risk, which is a continuing exposure for holders of sensitive health data.

What to watch next

Medibank has historically reported half-year results in February, which will be the first test of the FY27 outlook. The company's disclosures cover net policyholder growth, resident gross margins against the guidance, expense trends, the pace of any acquisitions and any further regulatory announcements on premiums or capital.

In short, FY26 was a steady rather than spectacular year, with a higher dividend and a cautious outlook. How that fits an individual's goals is for each reader to assess, ideally with licensed advice suited to their own circumstances.